Clinical trial
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV…
NCT00089219 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00089219 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma |
| Official title | Vaccination With Multiple Synthetic Melanoma Peptides Recognized by Helper T-Cells in Patients With Advanced Melanoma |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | IFA, 6MHP, GM-CSF |
| Enrollment | 39 |
| Start date | Jul 1, 2003 |
| Primary completion | May 1, 2006 |
| First posted | Aug 5, 2004 |
| Last update posted | Nov 20, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: